Cancer Genetics to Provide Corporate Update at 16th Annual BIO CEO & Investor Conference in New York
February 10 2014 - 4:01PM
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based
diagnostics, announced today that Panna Sharma, President and Chief
Executive Officer of Cancer Genetics, will provide a corporate
overview at the BIO CEO & Investor Conference, being held at
the Waldorf Astoria Hotel in New York City on February 10-11, 2014.
BIO CEO Presentation |
|
Date: |
Tuesday, February 11, 2014 |
Time: |
2:00pm Eastern Time |
Location: |
Waldorf Astoria Hotel, East Foyer Room, 3rd
Floor |
About the BIO CEO and Investor Conference
The BIO CEO & Investor Conference is the largest independent
investor conference focused on leading publicly-traded biotech
companies The meeting provides a neutral forum where institutional
investors, industry analysts, and senior biotechnology executives
can meet and have the opportunity to shape the future investment
landscape of the biotechnology industry. This year's conference
will feature presentations from more than 150 established public
and private biotech companies and non-profit funding organizations.
Approximately 1,400 delegates are expected to attend including 700
finance and investment professionals.
About Cancer Genetics Cancer Genetics, Inc. is
an emerging leader in DNA-based cancer diagnostics, servicing some
of the most prestigious medical institutions in the world. Our
tests target cancers that are difficult to diagnose and predict
treatment outcomes. These cancers include hematological, urogenital
and HPV-associated cancers. We also offer a comprehensive range of
non-proprietary oncology-focused tests and laboratory services that
provide critical genomic information to healthcare professionals,
as well as biopharma and biotech companies. Our state-of-the-art
reference lab is focused entirely on maintaining clinical
excellence and is both CLIA certified and CAP accredited and has
licensure from several states including New York State. We have
established strong research collaborations with major cancer
centers such as Memorial Sloan-Kettering, The Cleveland Clinic,
Mayo Clinic and the National Cancer Institute. For further
information, please see www.cancergenetics.com.
Forward Looking Statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements pertaining
to future financial and/or operating results, future growth in
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. products and services,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Company's Form 10-Q for the quarter ended September 30, 2013 and
other filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking
statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
jon@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024